Takeda FVE Reduction Leaves Shares Slightly Undervalued; Shire Acquisition Neutral to Valuation
We’ve slightly lowered our Takeda fair value estimate to JPY 5,100 from JPY 5,400 after incorporating the close of the Shire acquisition before the end of Takeda’s fiscal 2018 (we assume early calendar 2019) and mixed expectations for Takeda’s own portfolio this year and beyond, following the release of its fiscal 2017 financial results. Regarding Takeda’s valuation impact from the Shire acquisition, we think the deal is fairly neutral to our valuation; we see positive impacts (extra cash flows,...Takeda Pharmaceutical is a public company incorporated in Japan. Co. and its subsidiaries is a global pharmaceutical group and is engaged in the research, development, manufacturing and marketing of pharmaceutical products, over-the-counter (“OTC”) medicines and quasi-drug consumer products, and other healthcare products. Co.'s principal pharmaceutical products include medicines in the following therapeutic areas: gastroenterology, oncology and neuroscience.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.